how to administer glucagon

⚠️ Don’t Get It Wrong: How to Administer Glucagon for Emergency Use

Published: July 18, 2026 15:17 Author: Jason Moreau

Title: ⚠️ Don’t Get It Wrong: How to Administer Glucagon for Emergency Use Abstract: Glucagon, a 29-amino acid peptide hormone, is critical for reversing severe hypoglycemia via intramuscular/subcutaneous injection. The global peptide therapeutics market, valued at $40.5 billion in 2023, is projected to grow at 8.9% CAGR through 2030, driven by emergency glucagon kits. Leading brands (e.g., Eli Lilly’s Glucagon, Xeris’ Gvoke) differ in stability: traditional lyophilized powder requires reconstitution (risk of user error), while ready-to-use auto-injectors (Gvoke HypoPen) offer higher bioavailability (98% vs. 85%) and faster onset (10 min vs. 15 min). Key technical parameters include pH stability (2.5–3.5 for glucagon) and storage (room temperature vs. 2–8°C). Regulatory compliance (FDA, EMA) and GMP-certified manufacturing are mandatory. Selection criteria prioritize prefilled devices for layperson use, cold-chain logistics (2–8°C), and expiration tracking. Industry trends emphasize non-aqueous formulations to eliminate refrigeration.

Glucagon Administration Market Trends: Brand Comparison, Technical Pros & Cons, and Peptide Product Selection Guide

Published: July 13, 2026 14:01 Author: Laurent Harris

Abstract: The glucagon administration market is evolving rapidly, driven by innovations in peptide-based rescue therapies for severe hypoglycemia. This analysis compares leading brands (e.g., GlucaGen, Baqsimi, Gvoke) across technical pros and cons, including stability, reconstitution requirements, and delivery mechanisms (injectable vs. intranasal). Key product parameters—purity, bioavailability, and shelf-life—are benchmarked against regulatory certifications (FDA, EMA). Market trends highlight a shift toward ready-to-use auto-injectors and nasal powders, improving patient compliance. Selection criteria prioritize peptide composition, cold-chain logistics, and manufacturer GMP compliance. Industry data projects a 7.8% CAGR through 2030, with emerging biosimilars reshaping competitive dynamics. This guide synthesizes clinical efficacy, brand reputation, and supply chain integrity for informed procurement.